Histological mitotic count is a prognostic marker in vulvar sarcoma: a retrospective case series of 27 patients
Zejian Lin1, Haifeng Gu1, Guochen Liu1
1Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Abstract:
This retrospective study analyzed 27 vulvar sarcoma patients treated at one institution (2005-2024). Mitotic count significantly predicted outcomes: patients with ≥20 mitoses/high power field (HPF) (N = 8) showed drastically worse recurrence-free survival (recurrence-free survival; hazard ratio [HR] = 15.48, 95% confidence interval [CI] = 2.67-89.70, P < 0.01) and overall survival (HR = 11.97, 95% CI = 1.40-102.22, P = 0.02) versus those with 0-9/HPF (N = 12). Despite adjuvant therapy, the ≥20/HPF group experienced high local and distant recurrence rates (both 62.5%). Mitotic count is a robust prognostic indicator, with ≥20 mitoses/HPF indicating poor survival outcomes even after comprehensive treatment.
More Related Videos
09:17Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy
Published on: May 3, 2019
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
